Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 401–500 of 999

Mechanism of Action and Preclinical Profile of Raloxifene, a Selective Estrogen Receptor Modulator*
Bryant, H. U. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010019410881 · Cited by 49
Cardiovascular Effects of Raloxifene Hydrochloride
Saitta, A., Morabito, N., Frisina, N., Cucinotte, D., Corrado, F., D’Anna, R., Altavilla, D., Squadrito, G., Minutoli, L., Arcoraci, V., et al. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00183.x · Cited by 48
Overview of Women's Decision Making Regarding Elective Hysterectomy, Oophorectomy, and Hormone Replacement Therapy
Lewis, C. E., Groff, J. Y., Herman, C. J., McKeown, R. E., & Wilcox, L. S. (2000) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/152460900318722 · Cited by 48
“68 74–80 A meta-analysis on breast cancer risk with HRT that included 16 studies concluded that risk did not increase until after 5 years of use 81 and that after 15 years of estrogen therapy, the increased risk was 30%.”
Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function
Blum, A., & Cannon, R. O. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199812000-00010 · Cited by 48
Postmenopausal Estrogens—Opposed, Unopposed, or None of the Above
Willett, W. C. (2000) · JAMA · doi:10.1001/jama.283.4.534 · Cited by 48
Selective Estrogen Receptor Modulators and Postmenopausal Women's Health
Hol, T., COX, M. B., Bryant, H. U., & Draper, M. W. (1997) · Journal of Women s Health · doi:10.1089/jwh.1997.6.523 · Cited by 47
Redox Cycling of Catechol Estrogens Generating Apurinic/Apyrimidinic Sites and 8-oxo-Deoxyguanosine via Reactive Oxygen Species Differentiates Equine and Human Estrogens
Wang, Z., Chandrasena, E. R., Yuan, Y., Peng, K.-W., van Breemen, R. B., Thatcher, G. R. J., & Bolton, J. L. (2010) · Chemical Research in Toxicology · doi:10.1021/tx1001282 · Cited by 47
Avaliação tecnológica em saúde: densitometria óssea e terapêuticas alternativas na osteoporose pós-menopausa
Silva, L. K. (2003) · Cadernos de Saúde Pública · doi:10.1590/s0102-311x2003000400022 · Cited by 47
Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study
ROSNER, B. A., Colditz, G. A., Hankinson, S. E., Sullivan‐Halley, J., Lacey, J. V., & Bernstein, L. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2719-3 · Cited by 47
“Duration of current use of postmenopausal HT is significantly related to incidence of breast cancer [2, 18], and to type of menopause, age at menopause, and time since menopause.”
Background
Menopausal hormones and breast cancer in a biracial population
Moorman, P. G., Kuwabara, H., Millikan, R. C., & Newman, B. (2000) · American Journal of Public Health · doi:10.2105/ajph.90.6.966 · Cited by 47
“Our findings of no increased risk of breast cancer associated with menopausal hormone use are inconsistent with conclusions reached by the collaborative reanalysis and 2 major US cohort studies.(5,16,17) This outcome may be the result of having few long-term users in our population.”
Result
Anti-proliferative effects of estrogen receptor-modulating compounds isolated from Rheum palmatum
Kang, S. C., Lee, C. M., Choung, E. S., Bak, J. P., Bae, J. J., Yoo, H. S., Kwak, J. H., & Zee, O. P. (2008) · Archives of Pharmacal Research · doi:10.1007/s12272-001-1218-1 · Cited by 47
“…replacement therapy for menopause using synthetic estrogens has some side effects that include a slight but significant increase in the risk of developing breast and endometrial cancer due to unselective estrogenic action (Colditz et al., 1995, 1992; Henderson et al., 1988; Bolton et al., 1998).”
Background
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis
Migliaccio, S., Brama, M., & Spera, G. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.55 · Cited by 47
“Unfortunately, long-term ERT is associated with a number of undesirable side effects, including an increased risk of uterine and breast cancer and cardiovascular events (Barrett-Connor 1992; Compston 1992; Colditz et al 1995; Cauley et al 1996; WHI 2002).”
Background
Effect of soybean on breast cancer according to receptor status: a case-control study in Japan
Suzuki, T., Matsuo, K., Tsunoda, N., Hirose, K., Hiraki, A., Kawase, T., Yamashita, T., Iwata, H., Tanaka, H., & Tajima, K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23644 · Cited by 47
Efficacy and safety of oral estriol for managing postmenopausal symptoms
Takahashi, K., Manabe, A., Okada, M., Kurioka, H., Kanasaki, H., & Miyazaki, K. (2000) · Maturitas · doi:10.1016/s0378-5122(99)00108-5 · Cited by 47
“It has been well established, however, that unopposed estrogen administration may contribute significantly to the development of uterine endometrial cancer [1,2] and breast cancer [3,4].”
Background
Estrogen Decreases Expression of Chemokine Receptors, and Suppresses Chemokine Bioactivity in Murine Monocytes
Janis, K. L., Hoeltke, J., Nazareth, M. R., Fanti, P., Poppenberg, K., & Aronica, S. M. (2004) · American Journal of Reproductive Immunology · doi:10.1046/j.8755-8920.2003.00117.x · Cited by 47
“The length of time and amount of estrogen a woman is exposed to appears to be correlated with the chance of her developing breast cancer later in life.(2) Several different treatments have been developed to combat breast cancer including chemotherapy and different types of antiestrogens.”
Background
Phyto-oestrogens: A potential role in the prevention of CHD?
Cassidy, A., & Griffin, B. A. (1999) · Proceedings of The Nutrition Society · doi:10.1079/pns19990025 · Cited by 46
“Postmenopausal women are therefore faced with a dilemma; oestrogen use may protect against CHD and osteoporosis but may increase the risks of breast and endometrial cancer (Colditz et al. 1995; Col et al. 1997).”
Background
Reprint of Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?
Wuttke, W., Jarry, H., Becker, T., Schultens, A., Christoffel, V., Gorkow, C., & Seidlová‐Wuttke, D. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.11.012 · Cited by 46
Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women
Demétrio, F. N., Rennó, J., Gianfaldoni, A., Gonçalves, M. A., Halbe, H. W., Filho, A. H. G. V., & Gorenstein, C. (2011) · Archives of Women s Mental Health · doi:10.1007/s00737-011-0241-3 · Cited by 45
“However, studies suggesting significant adverse health effects of HRT (Farquhar 2002; Colditz et al. 1995; Kothari and Thacker 1999) sparked a heated debate over the adequacy of promoting this therapy and about subgroups that had greater benefit or risk (Shetty et al.”
Influential
Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Newcomb, P. A., Egan, K. M., Trentham‐Dietz, A., Titus-Ernstoff, L. T., Baron, J. A., Hampton, J. M., Stampfer, M. J., & Willett, W. C. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0610 · Cited by 46
“However, reduced breast cancer mortality has been observed among women using hormone therapy before breast cancer diagnosis in several studies (3-11).”
Background
Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives
Jørgensen, A. S., Jacobsen, P., Christiansen, L. B., Bury, P. S., Kanstrup, A., Thorpe, S. M., Nærum, L., & Wassermann, K. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00474-1 · Cited by 46
Menstrual Cycle Characteristics and Incidence of Premenopausal Breast Cancer
Terry, K. L., Willett, W. C., Rich-Edwards, J. W., Hunter, D. J., & Michels, K. B. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0051 · Cited by 46
“Subsequently, epidemiologic evidence has indicated that the combination of exogenous estrogen plus progestin increases the risk of breast cancer beyond the effect of estrogen alone (6, 7).”
Background
Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas
Chen, H., Liang, C., Lu, K., Lin, J., & Cho, C.-L. (2000) · Cancer · doi:10.1002/1097-0142(20001115)89:10 · Cited by 35
Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd]indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor
Jørgensen, A. S., Jacobsen, P., Christiansen, L., Bury, P. S., Kanstrup, A., Thorpe, S. M., Bain, S., Nærum, L., & Wassermann, K. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00015-9 · Cited by 47
Activation of estrogen receptor-β by a special extract of Rheum rhaponticum (ERr 731®), its aglycones and structurally related compounds
Wober, J., Möller, F. J., Richter, T., Unger, C., Weigt, C., Jandausch, A., Zierau, O., Rettenberger, R., Kaszkin-Bettag, M., & Vollmer, G. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.04.002 · Cited by 46
Antiestrogens Specifically Up-Regulate Bone Morphogenetic Protein-4 Promoter Activity in Human Osteoblastic Cells
van den Wijngaard, A., Mulder, W. R., Dijkema, R., Boersma, C. J. C., Mosselman, S., van Zoelen, E. J. J., & Olijve, W. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.5.0463 · Cited by 46
The Role of Tamoxifen in Breast Cancer Prevention
Wolmark, N., & Dunn, B. K. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04007.x · Cited by 46
Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation
Fowble, B. L., Hanlon, A. L., Freedman, G. M., Patchefsky, A., Kessler, H. B., Nicolaou, N., Hoffman, J., Sigurdson, E. R., Boraas, M. C., & Goldstein, L. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1680 · Cited by 46
Ethanol Modulates the Growth of Human Breast Cancer Cells In Vitro
Izevbigie, E. B., Ekunwe, S. I. N., Jordan, J., & Howard, C. B. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700406 · Cited by 45
The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials
Martino, S., Costantino, J. P., McNabb, M. A., Mershon, J. L., Bryant, K., Powles, T. J., & Secrest, R. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-116 · Cited by 45
Socioeconomic status differences in hormone therapy.
Marks, N., & Shinberg, D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009684 · Cited by 53
“promotion (8-15) and continuing controversy about its advisability as a therapeutic, preventive, or palliative health behavior (16-25).”
Background
Risks of Coronary Heart Disease in Women: Current Understanding and Evolving Concepts
Tsang, T. S. M., Barnes, M. E., Gersh, B. J., & Hayes, S. N. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.12.1289 · Cited by 45
Evidence That a Metabolite of Equine Estrogens, 4-Hydroxyequilenin, Induces Cellular Transformation in Vitro
Pisha, E., Lui, X., Constantinou, A. I., & Bolton, J. L. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000168y · Cited by 45
Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.
Haslam, S. Z., Osuch, J. R., Raafat, A. M., & Hofseth, L. J. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1015726608146 · Cited by 45
EFFECT OF SOLUBLE AND INSOLUBLE FIBER DIETS ON SERUM PROSTATE SPECIFIC ANTIGEN IN MEN
Tariq, N. A., Jenkins, D. J. A., Vidgen, E., Fleshner, N. E., Kendall, C. W. C., Story, J. A., Singer, W., D’Costa, M., & Struthers, N. W. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67985-2 · Cited by 44
Hormones and Breast Cancer: Evidence and Implications for Consideration of Risks and Benefits of Hormone Replacement Therapy
Colditz, G. A. (1999) · Journal of Women s Health · doi:10.1089/jwh.1999.8.347 · Cited by 44
“In the Nurses' Health Study, both incidence and mortality are elevated with longer durations of use.”
Influential
Postmenopausal Hormone Therapy and Mortality
Atkins, C. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371913 · Cited by 44
In vitro fertilization and breast cancer risk: a review.
Salhab, M., Al Sarakbi, W., & Mokbel, K. (2005) · PubMed · Cited by 43
Osteoporosis prevention and treatment
Sambrook, P. N., & Eisman, J. A. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb123917.x · Cited by 43
Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence?
YAFFE, K. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04024.x · Cited by 43
Comparative QSAR: On the Toxicology of the Phenolic OH Moiety
Garg, R., Kurup, A., & Hansch, C. H. (2001) · Critical Reviews in Toxicology · doi:10.1080/20014091111686 · Cited by 43
Breast cancer and hormone replacement therapy
LaCroix, A. Z., & Burke, W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)22041-6 · Cited by 43
MPA and postmenopausal coronary artery atherosclerosis revisited
Clarkson, T. B., & Appt, S. E. (2003) · Steroids · doi:10.1016/s0039-128x(03)00123-5 · Cited by 43
Menopause and post-menopause
Prelević, G. M., & Jacobs, H. S. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80317-5 · Cited by 42
Long-term postmenopausal estrogen therapy may be associated with increased risk of breast cancer: a cohort study
Ettinger, B. B., Quesenberry, C. P., Schroeder, D. A., & FRIEDMAN, G. D. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001216 · Cited by 42
Pathological review of internal genitalia after anterior exenteration for bladder cancer in women. Evaluating risk factors for female organ involvement
VARKARAKIS, I. M., Pinggera, G., Antoniou, N., Constantinides, K., Chrisofos, M., & Deliveliotis, C. (2007) · International Urology and Nephrology · doi:10.1007/s11255-006-9158-6 · Cited by 42
Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status
Dai, J., Jian, J., Bosland, M. C., Frenkel, K., Bernhardt, G., & Huang, X. (2007) · The Breast · doi:10.1016/j.breast.2007.08.009 · Cited by 42
Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada
Kirsh, V. A., & Kreiger, N. (2002) · Cancer Causes & Control · doi:10.1023/a:1016330024268 · Cited by 42
“43) [21-24].”
Breast cancer and post-menopausal hormone therapy
Kenemans, P., & Bosman, A. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00084-2 · Cited by 42
Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling, J. R., Malone, K. E., Doody, D. R., Voigt, L. F., Bernstein, L., Marchbanks, P. A., Coates, R. J., Norman, S. A., Weiss, L. K., Ursin, G., et al. (2003) · PubMed · Cited by 42
Assessing individual risk for breast cancer: risky business.
McTiernan, A., Gilligan, M., & Redmond, C. K. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00013-9 · Cited by 40
Elements of Informed Consent for Hormone Replacement Therapy in Patients With Diagnosed Breast Cancer
Chlebowski, R. T., & McTiernan, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.130 · Cited by 42
New developments in topical estrogen therapy
Jewelewicz, R. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81846-8 · Cited by 41
Inhibition of Glutathione S-Transferase Activity by the Quinoid Metabolites of Equine Estrogens
Chang, M., Zhang, F., Shen, L., Pauss, N., Alam, I., van Breemen, R. B., Blond, S. Y., & Bolton, J. L. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9702190 · Cited by 41
Choosing the Most Appropriate Treatment for Stable Angina
Asirvatham, S., Sebastian, C., & Thadani, U. (1998) · Drug Safety · doi:10.2165/00002018-199819010-00003 · Cited by 42
Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy
Pouillès, J. M., Trémollières, F., Roux, C., Sebert, J. L., Alexandra, C., Goldberg, D., Treves, R., Khalifa, P., Duntze, P., Horlait, S., et al. (1997) · Osteoporosis International · doi:10.1007/bf01622291 · Cited by 41
Digoxin use and risk of invasive breast cancer: evidence from the Nurses’ Health Study and meta-analysis
Ahern, T. P., Tamimi, R. M., ROSNER, B. A., & Hankinson, S. E. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2886-x · Cited by 40
“Second, the digoxin/breast cancer associations follow the same pattern as observed with exogenous hormone use: there is an elevated breast cancer risk among current users that wanes upon discontinuation [24, 38, 39].”
Norethisterone acetate in combination with estrogen: Effects on the skeleton and other organs
Riis, B. J., Lehmann, H.-J., & Christiansen, C. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.122852 · Cited by 40
Breast cancer: Risk factors, screening, and prevention
Gross, R. E. (2000) · Seminars in Oncology Nursing · doi:10.1053/sonc.2000.8110 · Cited by 40
Osteoporosis and breast cancer
Fontanges, É., Fontana, A., & Delmas, P. D. (2003) · Joint Bone Spine · doi:10.1016/j.jbspin.2003.02.001 · Cited by 40
The effects of six months of treatment with a low‐dose of conjugated oestrogens in menopausal women
Schlegel, W., Petersdorf, L. I., Junker, R., Schulte, H., Ebert, C., & von Eckardstein, A. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00857.x · Cited by 40
“However, HRT has also been associated with increases in the risk of breast cancer (Colditz et al., 1995) and venous thrombosis (Jicket al., 1996).”
Background
Bone Mineral Density and Risk of Breast Cancer: Differences by Family History of Breast Cancer
Lucas, F. L., Cauley, J. A., Stone, R. A., Cummings, S. R., Vogt, M. T., Weissfeld, J. L., & Kuller, L. H. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009554 · Cited by 40
Breast Augmentation: Compression???A Very Important Factor in Preventing Capsular Contracture
Camirand, A. (2000) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-200005000-00078 · Cited by 40
Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study
Shah, N. V., Seth, A., Balaraman, R., Sailor, G. U., Javia, A., & Gohil, D. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1408643 · Cited by 39
Hereditary Factors in Gynecologic Cancer
Lynch, H. T., Casey, M. J., Shaw, T. G., & Lynch, J. F. (1998) · The Oncologist · doi:10.1634/theoncologist.3-5-319 · Cited by 39
Women's attitudes towards menopause and hormone replacement therapy
Blumberg, G., Kaplan, B., Rabinerson, D., Goldman, G., Kitai, E., & Neri, A. (1996) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(96)02723-3 · Cited by 39
A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy
Grady, D. G. (2002) · JAMA · doi:10.1001/jama.287.16.2130 · Cited by 38
Measuring Estrogens and Progestagens in Humans: An Overview of Methods
Bellem, A., Meiyappan, S., Romans, S. E., & Einstein, G. (2011) · Gender Medicine · doi:10.1016/j.genm.2011.07.001 · Cited by 39
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women
Zeleznik, O. A., Balasubramanian, R., Zhao, Y., Frueh, L., Jeanfavre, S., Ávila-Pacheco, J., Clish, C. B., Tworoger, S. S., & Eliassen, A. H. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00262-4 · Cited by 37
Hormone replacement therapy: clinical benefits and side-effects
Lignieres, B. D. (1996) · Maturitas · doi:10.1016/0378-5122(96)01009-2 · Cited by 38
Hormone Replacement Therapy: Real Concerns and False Alarms
Bluming, A. Z., & Tavris, C. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e31819e332a · Cited by 40
Attitudes of Obstetricians and Gynecologists toward Hormone Replacement Therapy
Baron, J., Holzman, G. B., & Schulkin, J. A. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800408 · Cited by 38
Recent oral contraceptive use and risk of breast cancer (United States)
Newcomb, P. A., Longnecker, M. P., Storer, B. E., Mittendorf, R., Baron, J. A., Clapp, R., Trentham‐Dietz, A., & Willett, W. C. (1996) · Cancer Causes & Control · doi:10.1007/bf00051885 · Cited by 38
Mutagenic Properties of Estrogen Quinone-Derived DNA Adducts in Simian Kidney Cells
Terashima, I., Suzuki, N., & Shibutani, S. (2000) · Biochemistry · doi:10.1021/bi002273c · Cited by 38
Menopause and breast cancer: Symptoms, late effects, and their management
Ganz, P. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90120-4 · Cited by 38
Risk of breast and ovarian cancer in women with strong family histories.
Srivastava, A., McKinnon, W. C., & Wood, M. E. (2001) · PubMed · Cited by 38
A protective effect of Curcuma comosa Roxb. on bone loss in estrogen deficient mice
Weerachayaphorn, J., Chuncharunee, A., Mahagita, C., Lewchalermwongse, B., Suksamrarn, A., & Piyachaturawat, P. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.06.040 · Cited by 37
Rhodiola crenulata induces an early estrogenic response and reduces proliferation and tumorsphere formation over time in MCF7 breast cancer cells.
Bassa, L., Jacobs, C., Gregory, K. J., Henchey, E., Ser-Dolansky, J., & Schneider, S. (2016) · Phytomedicine · doi:10.1016/j.phymed.2015.11.014 · Cited by 33
Hormone Therapy Use and Risk of Chronic Disease in the Nurses’ Health Study: A Comparative Analysis With the Women's Health Initiative
Bhupathiraju, S. N., Grodstein, F., ROSNER, B. A., Stampfer, M. J., Hu, F. B., Willett, W. C., & Manson, J. E. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx131 · Cited by 37
“3 Findings from observational studies have suggested that menopausal hormone therapy (HT) use is associated with a lower risk of coronary heart disease (CHD), hip fracture, and all-cause mortality, but with a higher risk of breast cancer, stroke, and pulmonary embolism (1-6).”
The Effect of Hormone Replacement Therapy on Oxidized Low Density Lipoprotein Levels and Paraoxonase Activity in Postmenopausal Women
Topçuoğlu, A., Uzun, H., Aydın, S., Kahraman, N., Vehid, S., Zeybek, G., & Topçuoǧlu, D. (2004) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.205.79 · Cited by 37
Bilateral acute anterior uveitis after alendronate
Malik, A. R. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.12.1443 · Cited by 37
Structural and Functional Consequences of Inactivation of Human Glutathione S -Transferase P1-1 Mediated by the Catechol Metabolite of Equine Estrogens, 4-Hydroxyequilenin
Chang, M., Shin, Y. G., van Breemen, R. B., Blond, S. Y., & Bolton, J. L. (2001) · Biochemistry · doi:10.1021/bi002513o · Cited by 37
A population-based cohort study of HRT use and breast cancer in southern Sweden
Olsson, H. L., Bladström, A., Ingvar, C., & Möller, T. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1899 · Cited by 37
“Only a few cohort investigations exist (Mills et al, 1989; Hunt et al, 1990; Risch and Howe, 1994; Colditz et al, 1995; Persson, 1996; Lando et al, 1999; Schairer et al, 2000) and most studies find an increased incidence or mortality of breast cancer (Mills et al, 1989; Hunt et al, 1990; Risch and…”
Background
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations
Casey, M. J., & Bewtra, C. (2004) · Familial Cancer · doi:10.1007/s10689-004-9554-y · Cited by 37
Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics and bone mass in rats
Bauss, F., Eßwein, A., Reiff, K., Sponer, G., & Müller‐Beckmann, B. (1996) · Calcified Tissue International · doi:10.1007/s002239900104 · Cited by 37
Biological Effects of Hormone Replacement Therapy in Relation to Serum Estradiol Levels
Yasui, T., Uemura, H., Tezuka, M., Yamada, M., Irahara, M., Miura, M., & Aono, T. (2001) · Hormone Research in Paediatrics · doi:10.1159/000048088 · Cited by 37
Menopausal hormone therapy and breast cancer mortality: clinical implications
Chlebowski, R. T., & Anderson, G. L. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614568300 · Cited by 36
Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms
Strong, A. L., Ohlstein, J. F., Jiang, Q., Zhang, Q., Zheng, S., Boué, S. M., Elliott, S. G., Gimble, J. M., Burow, M. E., Wang, G., et al. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt493 · Cited by 36
“Furthermore, while estrogens are considered powerful modulators of bone metabolism by reducing the development of osteoporosis and increasing BMD, their use in the form of hormone replacement therapy has been halted due to its association with an increased risk of developing breast and endometrial cancer [11-13].”
Background
Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies
Yu, X., Zhou, S., Wang, J., Zhang, Q., Hou, J., Zhu, L., He, Y., Zhao, J., & Zhong, S. (2017) · Breast Cancer · doi:10.1007/s12282-017-0789-5 · Cited by 36
Novel indolizine derivatives lowers blood glucose levels in streptozotocin-induced diabetic rats: A histopathological approach
Tatipamula, V. B., Kolli, M. K., Lagu, S. B., Paidi, K. R., Raveendra Reddy, P., & Yejella, R. P. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.11.004 · Cited by 36
Hormone Replacement Therapy and Hip Fracture Risk: Effect Modification by Tobacco Smoking, Alcohol Intake, Physical Activity, and Body Mass Index
Høidrup, S., k, M. G. N., Pedersen, A. T., Lauritzen, J. B., Gottschau, A., & Schroll, M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009933 · Cited by 36
“balance potential adverse effects of long-term HRT, including increased risk for breast cancer, venous thromboembolism, and pulmonary embolism (12-14), strategies to identify the subset of women who achieve the largest degree of protection against fracture from the treatment must be determined.”
Background
Perimenopausal and postmenopausal hormone replacement therapy Part 1. An update of the literature on benefits and risks*1
Lichtman, R. (1996) · Journal of Nurse-Midwifery · doi:10.1016/0091-2182(95)00082-8 · Cited by 36
Theoretical basis for the benefit of postmenopausal estrogen substitution
Miller, M. M., & Franklin, K. B. J. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00032-7 · Cited by 36
Hormone-Replacement Therapy — Breast versus Heart versus Bone
Davidson, N. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322409 · Cited by 36
Postmenopausal Hormone Use, Screening, and Breast Cancer: Characterization and Control of a Bias
Joffe, M. M., Byrne, C., & Colditz, G. A. (2001) · Epidemiology · doi:10.1097/00001648-200107000-00013 · Cited by 35
“This stratum-specific divergence in the log relative risk depends on the following stratum-specific quantities: (1) the proportion S of PMH nonusers who are not screened in the following interval; (2) the effect D of PMH on the proportion screened (on a probability difference scale); and (3) the effects R0 and R1 of s…”
Background
Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. IV Effects of Osteotropic Estradiol on Bone Mineral Density and Uterine Weight in Ovariectomized Rats
Fujisaki, J., Tokunaga, Y., Takahashi, T., Shimojo, F., Kimura, S., & Hata, T. (1998) · Journal of drug targeting · doi:10.3109/10611869808995866 · Cited by 35
Age at Menopause: Imputing Age at Menopause for Women With a Hysterectomy With Application to Risk of Postmenopausal Breast Cancer
ROSNER, B. A., & Colditz, G. A. (2011) · Annals of Epidemiology · doi:10.1016/j.annepidem.2011.02.010 · Cited by 35
“Even others assume age at menopause is the age at hysterectomy (13).”
Background
Environmental dichlorodiphenyltrichlorethane or hexachlorobenzene exposure and breast cancer: is there a risk?
Charlier, C., Foidart, J., Pitance, F., Herman, P., GASPARD, U. J., Meurisse, M., & Plomteux, G. J. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.040 · Cited by 35
“41 (14) increased risk of breast cancer.”
Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk
Henrich, J. B., Kornguth, P. J., Viscoli, C. M., & Horwitz, R. I. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00116-4 · Cited by 35
“In reviewing these studies, only nine based their analyses on women with invasive breast cancer specifically or provided separate information for in situ and invasive disease [3,8,16–18,23,26,32, 34].”
Background
Estrogens and breast cancer
Hankinson, S. E., & Stampfer, M. J. (1997) · Salud Pública de México · doi:10.1590/s0036-36341997000400014 · Cited by 35
Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential
Margolis, R., CANALIS, E. M., & Partridge, N. C. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772542 · Cited by 35

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks